Paper: Early Integration of High Dose Methotrexate to Frontline DLBCL Therapy Does Not Impact CNS Relapse Compared to End of Treatment Delivery: A Multicentre International Analysis of 1384 Patients
Analysis of 1,384 lymphoma patients treated with CNS prophylaxis compared intercalated HD MTX with end of treatment HD MTX. There was no difference seen in CNS relapse rates between the groups. When limited analysis to 600 high risk CNS IPI patients the 3 year CNS relapse rate was ~9% without a difference between the groups. Intercalated treatment was associated with delays in RCHOP delivery. Exploratory analysis on patients with isolated CNS relapse also showed no difference in relapse rates between treatment arms.
